Zurich (awp) – Sandoz, a subsidiary of Novartis specializing in generics and biosimilars, announced Thursday that it has won the marketing of products from the Indian laboratory Adalvo in the United States.
In the field of anti-infectives and oncology, the six non-patented drugs from the pharmaceutical company Adalvo will be marketed exclusively by Sandoz, reports a press release.
The launch of these products in the United States is planned from 2024. The addressable market is estimated at 3 billion dollars.
one/fr
2023-05-04 06:16:04
#Sandoz #signs #distribution #agreement #United #States
:watermark(https://f.pmo.ee//logos/4132/d583334e07b643b158b745b655f05032.png,-2p,-2p,0,18,none)/nginx/o/2023/02/18/15146156t1h648f.jpg?resize=150%2C150&ssl=1)
